Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Angiogenesis
Published in: Angiogenesis 2/2009

01-06-2009 | Original Paper

Vasculogenesis in infantile hemangioma

Authors: Elisa Boscolo, Joyce Bischoff

Published in: Angiogenesis | Issue 2/2009

Login to get access

Abstract

Infantile hemangioma is a vascular tumor that occurs in 5–10% of infants of European descent. A defining feature of infantile hemangioma is the dramatic growth and development into a disorganized mass of blood vessels. Subsequently, a slow spontaneous involution begins around 1 year of age and continues for 4–6 years. The growth and involution of infantile hemangioma is very different from other vascular tumors and vascular malformations, which do not regress and can occur at any time during childhood or adult life. Much has been learned from careful study of the tissue morphology and gene expression patterns during the life-cycle of hemangioma. Tissue explants and tumor-derived cell populations have provided further insight to unravel the cellular and molecular basis of infantile hemangioma. A multipotent progenitor cell capable of de novo blood vessel formation has been isolated from infantile hemangioma, which suggests that this common tumor of infancy, long considered to be a model for pathologic angiogenesis, may also represent pathologic vasculogenesis. Whether viewed as angiogenesis or vasculogenesis, infantile hemangioma represents a vascular perturbation during a critical period of post-natal growth, and as such provides a unique opportunity to decipher mechanisms of human vascular development.
Literature
1.
2.
3.
Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, Horii KA, Lucky AW, Mancini AJ, Metry DW, Newell B et al (2007) Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 150:291–294PubMedCrossRef
4.
Frieden IJ, Haggstrom AN, Drolet BA, Mancini AJ, Friedlander SF, Boon L, Chamlin SL, Baselga E, Garzon MC, Nopper AJ et al (2005) Infantile hemangiomas: current knowledge, future directions. In: Proceedings of a research workshop on infantile hemangiomas, April 7–9, 2005, Bethesda. Pediatr Dermatol 22:383–406
5.
Metry DW, Haggstrom AN, Drolet BA, Baselga E, Chamlin S, Garzon M, Horii K, Lucky A, Mancini AJ, Newell B et al (2006) A prospective study of PHACE syndrome in infantile hemangiomas: demographic features, clinical findings, and complications. Am J Med Genet A 140:975–986PubMed
6.
Huang SA, Tu HM, Harney JW, Venihaki M, Butte AJ, Kozakewich HP, Fishman SJ, Larsen PR (2000) Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med 343:185–189PubMedCrossRef
7.
Boon LM, MacDonald DM, Mulliken JB (1999) Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg 104:1616–1623PubMedCrossRef
8.
Enjolras O, Breviere GM, Roger G, Tovi M, Pellegrino B, Varotti E, Soupre V, Picard A, Leverger G (2004) Vincristine treatment for function- and life-threatening infantile hemangioma. Arch Pediatr 11:99–107PubMedCrossRef
9.
Fawcett SL, Grant I, Hall PN, Kelsall AW, Nicholson JC (2004) Vincristine as a treatment for a large haemangioma threatening vital functions. Br J Plast Surg 57:168–171PubMedCrossRef
10.
Ezekowitz RA, Mulliken JB, Folkman J (1992) Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 326:1456–1463PubMed
11.
Chang E, Boyd A, Nelson CC, Crowley D, Law T, Keough KM, Folkman J, Ezekowitz RA, Castle VP (1997) Successful treatment of infantile hemangiomas with interferon-alpha-2b. J Pediatr Hematol Oncol 19:237–244PubMedCrossRef
12.
Barlow CF, Priebe CJ, Mulliken JB, Barnes PD, Mac Donald D, Folkman J, Ezekowitz RA (1998) Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy. J Pediatr 132:527–530PubMedCrossRef
13.
Greinwald JH Jr, Burke DK, Bonthius DJ, Bauman NM, Smith RJ (1999) An update on the treatment of hemangiomas in children with interferon alfa-2a. Arch Otolaryngol Head Neck Surg 125:21–27PubMed
14.
Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A (2008) Propranolol for severe hemangiomas of infancy. N Engl J Med 358:2649–2651PubMedCrossRef
15.
Chang LC, Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, Horii KA, Lucky AW, Mancini AJ, Metry DW et al (2008) Growth characteristics of infantile hemangiomas: implications for management. Pediatrics 122:360–367PubMedCrossRef
16.
Mancini AJ, Smoller BR (1996) Proliferation and apoptosis within juvenile capillary hemangiomas. Am J Dermatopathol 18:505–514PubMedCrossRef
17.
Smoller BR, Apfelberg DB (1993) Infantile (juvenile) capillary hemangioma: a tumor of heterogeneous cellular elements. J Cutan Pathol 20:330–336PubMedCrossRef
18.
Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA (1994) Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 93:2357–2364PubMedCrossRef
19.
Chang J, Most D, Bresnick S, Mehrara B, Steinbrech DS, Reinisch J, Longaker MT, Turk AE (1999) Proliferative hemangiomas: analysis of cytokine gene expression and angiogenesis. Plast Reconstr Surg 103:1–9 (discussion 10)PubMedCrossRef
20.
Picard A, Boscolo E, Khan ZA, Bartch TC, Mulliken JB, Vazquez MP, Bischoff J (2008) IGF-2 and FLT-1/VEGF-R1 mRNA levels reveal distinctions and similarities between congenital and common infantile hemangioma. Pediatr Res 63:263–267PubMedCrossRef
21.
Yu Y, Varughese J, Brown LF, Mulliken JB, Bischoff J (2001) Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. Am J Pathol 159:2271–2280PubMed
22.
Yu Y, Flint AF, Mulliken JB, Wu JK, Bischoff J (2004) Endothelial progenitor cells in infantile hemangioma. Blood 103:1373–1375PubMedCrossRef
23.
North PE, Waner M, Mizeracki A, Mrak RE, Nicholas R, Kincannon J, Suen JY, Mihm MC Jr (2001) A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol 137:559–570PubMed
24.
Barnes CM, Huang S, Kaipainen A, Sanoudou D, Chen EJ, Eichler GS, Guo Y, Yu Y, Ingber DE, Mulliken JB et al (2005) Evidence by molecular profiling for a placental origin of infantile hemangioma. Proc Natl Acad Sci USA 102:19097–19102PubMedCrossRef
25.
Barnes CM, Christison-Lagay EA, Folkman J (2007) The placenta theory and the origin of infantile hemangioma. Lymphat Res Biol 5:245–255PubMedCrossRef
26.
Chang EI, Chang EI, Thangarajah H, Hamou C, Gurtner GC (2007) Hypoxia, hormones, and endothelial progenitor cells in hemangioma. Lymphat Res Biol 5:237–243PubMedCrossRef
27.
Pittman KM, Losken HW, Kleinman ME, Marcus JR, Blei F, Gurtner GC, Marchuk DA (2006) No evidence for maternal-fetal microchimerism in infantile hemangioma: a molecular genetic investigation. J Invest Dermatol 126:2533–2538PubMedCrossRef
28.
Regnier S, Dupin N, Le Danff C, Wassef M, Enjolras O, Aractingi S (2007) Endothelial cells in infantile haemangiomas originate from the child and not from the mother (a fluorescence in situ hybridization-based study). Br J Dermatol 157:158–160PubMedCrossRef
29.
Bauland CG, van Steensel MA, Steijlen PM, Rieu PN, Spauwen PH (2006) The pathogenesis of hemangiomas: a review. Plast Reconstr Surg 117:29e–35ePubMedCrossRef
30.
Pack GT, Miller TR (1950) Hemangiomas; classification, diagnosis and treatment. Angiology 1:405–426PubMedCrossRef
31.
Virchow R (1863) Die Krankhaften Geschwulste. August Hirschwald, Berlin
32.
Pack G (1950) Hemangiomas, classification, diagnosis, and treatment. Angiology 1:40CrossRef
33.
Malan E (1974) Vascular Malformations (Angiodysplasias). Carlo Erba Foundation, Milan, p 4
34.
Mulliken JB, Zetter BR, Folkman J (1982) In vitro characteristics of endothelium from hemangiomas and vascular malformations. Surgery 92:348–353PubMed
35.
Dosanjh A, Chang J, Bresnick S, Zhou L, Reinisch J, Longaker M, Karasek M (2000) In vitro characteristics of neonatal hemangioma endothelial cells: similarities and differences between normal neonatal and fetal endothelial cells. J Cutan Pathol 27:441–450PubMedCrossRef
36.
Boye E, Yu Y, Paranya G, Mulliken JB, Olsen BR, Bischoff J (2001) Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest 107:745–752PubMedCrossRef
37.
Dadras SS, North PE, Bertoncini J, Mihm MC, Detmar M (2004) Infantile hemangiomas are arrested in an early developmental vascular differentiation state. Mod Pathol 17:1068–1079PubMedCrossRef
38.
Walter JW, North PE, Waner M, Mizeracki A, Blei F, Walker JW, Reinisch JF, Marchuk DA (2002) Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes Chromosomes Cancer 33:295–303PubMedCrossRef
39.
Khan ZA, Melero-Martin JM, Wu X, Paruchuri S, Boscolo E, Mulliken JB, Bischoff J (2006) Endothelial progenitor cells from infantile hemangioma and umbilical cord blood display unique cellular responses to endostatin. Blood 108:915–921PubMedCrossRef
40.
O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277–285PubMedCrossRef
41.
Kleinman ME, Tepper OM, Capla JM, Bhatt KA, Ceradini DJ, Galiano RD, Blei F, Levine JP, Gurtner GC (2003) Increased circulating AC133+ CD34+ endothelial progenitor cells in children with hemangioma. Lymphat Res Biol 1:301–307PubMedCrossRef
42.
Ozerdem U, Grako KA, Dahlin-Huppe K, Monosov E, Stallcup WB (2001) NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis. Dev Dyn 222:218–227PubMedCrossRef
43.
Tigges U, Hyer EG, Scharf J, Stallcup WB (2008) FGF2-dependent neovascularization of subcutaneous Matrigel plugs is initiated by bone marrow-derived pericytes and macrophages. Development 135:523–532PubMedCrossRef
44.
Li Q, Yu Y, Bischoff J, Mulliken JB, Olsen BR (2003) Differential expression of CD146 in tissues and endothelial cells derived from infantile haemangioma and normal human skin. J Pathol 201:296–302PubMedCrossRef
45.
Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, Andriolo G, Sun B, Zheng B, Zhang L et al (2008) A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3:301–313PubMedCrossRef
46.
Tang W, Zeve D, Suh JM, Bosnakovski D, Kyba M, Hammer RE, Tallquist MD, Graff JM (2008) White fat progenitor cells reside in the adipose vasculature. Science 322:583–586PubMedCrossRef
47.
Khan ZA, Boscolo E, Picard A, Psutka S, Melero-Martin JM, Bartch TC, Mulliken JB, Bischoff J (2008) Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. J Clin Invest 118:2592–2599PubMed
48.
Ritter MR, Dorrell MI, Edmonds J, Friedlander SF, Friedlander M (2002) Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. Proc Natl Acad Sci USA 99:7455–7460PubMedCrossRef
49.
North PE, Waner M, Mizeracki A, Mihm MC Jr (2000) GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 31:11–22PubMedCrossRef
50.
Melero-Martin JM, De Obaldia ME, Kang SY, Khan ZA, Yuan L, Oettgen P, Bischoff J (2008) Engineering robust and functional vascular networks in vivo with human adult and cord blood-derived progenitor cells. Circ Res 103:194–202PubMedCrossRef
51.
52.
Au P, Tam J, Fukumura D, Jain RK (2008) Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. Blood 111:4551–4558PubMedCrossRef
53.
Tan ST, Wallis RA, He Y, Davis PF (2004) Mast cells and hemangioma. Plast Reconstr Surg 113:999–1011PubMedCrossRef
54.
Pasyk KA, Cherry GW, Grabb WC, Sasaki GH (1984) Quantitative evaluation of mast cells in cellularly dynamic and adynamic vascular malformations. Plast Reconstr Surg 73:69–77PubMedCrossRef
55.
Ritter MR, Reinisch J, Friedlander SF, Friedlander M (2006) Myeloid cells in infantile hemangioma. Am J Pathol 168:621–628PubMedCrossRef
56.
Nguyen VA, Furhapter C, Romani N, Weber F, Sepp N (2004) Infantile hemangioma is a proliferation of beta 4-negative endothelial cells adjacent to HLA-DR-positive cells with dendritic cell morphology. Hum Pathol 35:739–744PubMedCrossRef
57.
Jang YC, Isik FF, Gibran NS (2000) Nerve distribution in hemangiomas depends on the proliferative state of the microvasculature. J Surg Res 93:144–148PubMedCrossRef
58.
Berard M, Sordello S, Ortega N, Carrier JL, Peyri N, Wassef M, Bertrand N, Enjolras O, Drouet L, Plouet J (1997) Vascular endothelial growth factor confers a growth advantage in vitro and in vivo to stromal cells cultured from neonatal hemangiomas. Am J Pathol 150:1315–1326PubMed
59.
Jinnin M, Medici D, Park L, Limaye N, Liu Y, Boscolo E, Bischoff J, Vikkula M, Boye E, Olsen BR (2008) Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med 14:1236–1246PubMedCrossRef
60.
Zhang L, Lin X, Wang W, Zhuang X, Dong J, Qi Z, Hu Q (2005) Circulating level of vascular endothelial growth factor in differentiating hemangioma from vascular malformation patients. Plast Reconstr Surg 116:200–204PubMedCrossRef
61.
Fong GH, Rossant J, Gertsenstein M, Breitman ML (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66–70PubMedCrossRef
62.
Blei F, Walter J, Orlow SJ, Marchuk DA (1998) Familial segregation of hemangiomas and vascular malformations as an autosomal dominant trait. Arch Dermatol 134:718–722PubMedCrossRef
63.
Walter JW, Blei F, Anderson JL, Orlow SJ, Speer MC, Marchuk DA (1999) Genetic mapping of a novel familial form of infantile hemangioma. Am J Med Genet 82:77–83PubMedCrossRef
64.
Pramanik K, Chun CZ, Garnaas MK, Samant GV, Li K, Horswill MA, North PE, Ramchandran R (2009) Dusp-5 and Snrk-1 coordinately function during vascular development and disease. Blood 113:1184–1191PubMedCrossRef
65.
Qian F, Zhen F, Ong C, Jin SW, Meng Soo H, Stainier DY, Lin S, Peng J, Wen Z (2005) Microarray analysis of zebrafish cloche mutant using amplified cDNA and identification of potential downstream target genes. Dev Dyn 233:1163–1172PubMedCrossRef
66.
Sumanas S, Jorniak T, Lin S (2005) Identification of novel vascular endothelial-specific genes by the microarray analysis of the zebrafish cloche mutants. Blood 106:534–541PubMedCrossRef
67.
St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B et al (2000) Genes expressed in human tumor endothelium. Science 289:1197–1202PubMedCrossRef
68.
Arbiser JL, Weiss SW, Arbiser ZK, Bravo F, Govindajaran B, Caceres-Rios H, Cotsonis G, Recavarren S, Swerlick RA, Cohen C (2001) Differential expression of active mitogen-activated protein kinase in cutaneous endothelial neoplasms: implications for biologic behavior and response to therapy. J Am Acad Dermatol 44:193–197PubMedCrossRef
69.
Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87:1171–1180PubMedCrossRef
70.
Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N et al (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55–60PubMedCrossRef
71.
Hawighorst T, Skobe M, Streit M, Hong YK, Velasco P, Brown LF, Riccardi L, Lange-Asschenfeldt B, Detmar M (2002) Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am J Pathol 160:1381–1392PubMed
72.
Stoeltzing O, Ahmad SA, Liu W, McCarty MF, Parikh AA, Fan F, Reinmuth N, Bucana CD, Ellis LM (2002) Angiopoietin-1 inhibits tumour growth and ascites formation in a murine model of peritoneal carcinomatosis. Br J Cancer 87:1182–1187PubMedCrossRef
73.
Feng Y, vom Hagen F, Pfister F, Djokic S, Hoffmann S, Back W, Wagner P, Lin J, Deutsch U, Hammes HP (2007) Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpression. Thromb Haemost 97:99–108PubMed
74.
Perry BN, Govindarajan B, Bhandarkar SS, Knaus UG, Valo M, Sturk C, Carrillo CO, Sohn A, Cerimele F, Dumont D et al (2006) Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. J Invest Dermatol 126:2316–2322PubMedCrossRef
75.
Sun JF, Phung T, Shiojima I, Felske T, Upalakalin JN, Feng D, Kornaga T, Dor T, Dvorak AM, Walsh K et al (2005) Microvascular patterning is controlled by fine-tuning the Akt signal. Proc Natl Acad Sci USA 102:128–133PubMedCrossRef
76.
Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah G, Riveros M, Perruzzi C, Sun J, Monahan-Earley RA, Shiojima I, Nagy JA et al (2006) Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 10:159–170PubMedCrossRef
77.
Kleinman ME, Greives MR, Churgin SS, Blechman KM, Chang EI, Ceradini DJ, Tepper OM, Gurtner GC (2007) Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma. Arterioscler Thromb Vasc Biol 27:2664–2670PubMedCrossRef
78.
Isik FF, Rand RP, Gruss JS, Benjamin D, Alpers CE (1996) Monocyte chemoattractant protein-1 mRNA expression in hemangiomas and vascular malformations. J Surg Res 61:71–76PubMedCrossRef
79.
Kraling BM, Razon MJ, Boon LM, Zurakowski D, Seachord C, Darveau RP, Mulliken JB, Corless CL, Bischoff J (1996) E-selectin is present in proliferating endothelial cells in human hemangiomas. Am J Pathol 148:1181–1191PubMed
80.
Oh IY, Yoon CH, Hur J, Kim JH, Kim TY, Lee CS, Park KW, Chae IH, Oh BH, Park YB et al (2007) Involvement of E-selectin in recruitment of endothelial progenitor cells and angiogenesis in ischemic muscle. Blood 110:3891–3899PubMedCrossRef
81.
Gainers ME, Descheny L, Barthel SR, Liu L, Wurbel MA, Dimitroff CJ (2007) Skin-homing receptors on effector leukocytes are differentially sensitive to glyco-metabolic antagonism in allergic contact dermatitis. J Immunol 179:8509–8518PubMed
82.
Hidalgo A, Weiss LA, Frenette PS (2002) Functional selectin ligands mediating human CD34(+) cell interactions with bone marrow endothelium are enhanced postnatally. J Clin Invest 110:559–569PubMed
Metadata
Title
Vasculogenesis in infantile hemangioma
Authors
Elisa Boscolo
Joyce Bischoff
Publication date
01-06-2009
Publisher
Springer Netherlands
Published in
Angiogenesis / Issue 2/2009
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-009-9148-2

Other articles of this Issue 2/2009

Angiogenesis 2/2009 Go to the issue

Original Paper

Morphological and molecular aspects of physiological vascular morphogenesis

Original Paper

Endogenous endothelial cell signaling systems maintain vascular stability

Original Paper

Semaphorins and tumor angiogenesis

Review Paper

Fibronectins in vascular morphogenesis

Erratum

Semaphorins and tumor angiogenesis

Original Paper

Intussusceptive angiogenesis and its role in vascular morphogenesis, patterning, and remodeling
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits